Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Nov 22;7(47):77958-77967.
doi: 10.18632/oncotarget.12862.

CD99 Polymorphisms Significantly Influence the Probability to Develop Ewing Sarcoma in Earlier Age and Patient Disease Progression

Affiliations
Free PMC article

CD99 Polymorphisms Significantly Influence the Probability to Develop Ewing Sarcoma in Earlier Age and Patient Disease Progression

Marcella Martinelli et al. Oncotarget. .
Free PMC article

Abstract

Ewing sarcoma (EWS), the second most common primary bone tumor in pediatric age, is known for its paucity of recurrent somatic abnormalities. Apart from the chimeric oncoprotein that derives from the fusion of EWS and FLI genes, recent genome-wide association studies have identified susceptibility variants near the EGR2 gene that regulate DNA binding of EWS-FLI. However, to induce transformation, EWS-FLI requires the presence of additional molecular events, including the expression of CD99, a cell surface molecule with critical relevance for the pathogenesis of EWS. High expression of CD99 is a common and distinctive feature of EWS cells, and it has largely been used for the differential diagnosis of the disease. The present study first links CD99 germline genetic variants to the susceptibility of EWS development and its progression. In particular, a panel of 25 single nucleotide polymorphisms has been genotyped in a case-control study. The CD99 rs311059 T variant was found to be significantly associated [P value = 0.0029; ORhet = 3.9 (95% CI 1.5-9.8) and ORhom = 5.3 (95% CI 1.2-23.7)] with EWS onset in patients less than 14 years old, while the CD99 rs312257-T was observed to be associated [P value = 0.0265; ORhet = 3.5 (95% CI 1.3-9.9)] with a reduced risk of relapse. Besides confirming the importance of CD99, our findings indicate that polymorphic variations in this gene may affect either development or progression of EWS, leading to further understanding of this cancer and development of better diagnostics/prognostics for children and adolescents with this devastating disease.

Keywords: CD99; Ewing sarcoma; association analysis; polymorphisms.

Conflict of interest statement

CONFLICTS OF INTEREST

No potential conflicts of interest were disclosed by the authors.

Figures

Figure 1
Figure 1. Prognostic impact of the presence of CD99 rs312257 T allele according to Kaplan–Meier curves and log-rank test
EWS patients were classified for the presence (POS) or absence (NEG) of the variant. Event-free survival (EFS) was considered.

Similar articles

See all similar articles

Cited by 1 article

References

    1. Burchill SA. Ewing's sarcoma: diagnostic, prognostic, and therapeutic implications of molecular abnormalities. Journal of clinical pathology. 2003;56:96–102. - PMC - PubMed
    1. Linden G, Dunn JE. Ewing's sarcoma in Negroes. Lancet. 1970;1:1171. - PubMed
    1. Jensen RD, Drake RM. Rarity of Ewing's tumour in Negroes. Lancet. 1970;1:777. - PubMed
    1. Li FP, Tu JT, Liu FS, Shiang EL. Rarity of Ewing's sarcoma in China. Lancet. 1980;1:1255. - PubMed
    1. Jawad MU, Cheung MC, Min ES, Schneiderbauer MM, Koniaris LG, Scully SP. Ewing sarcoma demonstrates racial disparities in incidence-related and sex-related differences in outcome: an analysis of 1631 cases from the SEER database, 1973-2005. Cancer. 2009;115:3526–3536. - PubMed
Feedback